Intelligence · Clinical Pipeline
Anaxis Pharma Pipeline
All ClinicalTrials.gov programs at Anaxis Pharma — phase, modality, and trial IDs.
- Programs
- 198
Quick answer
Anaxis Pharma has 198 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
bimekizumab
Lacuna Pharma Pty Ltd
Hidradenitis Suppurativa
1 trial -
bimekizumab, Skyrizi 150 mg solution for injection in pre-filled syringe, Placebo matching test and comparator. 0.9% sodium chloride solution for injection (unauthorized).
Lacuna Pharma Pty Ltd
Psoriatic arthritis
1 trial -
brivaracetam, -, -, brivaracetam, -, brivaracetam, Placebo matching < brivaracetam oral solution> and without active substance
Lacuna Pharma Pty Ltd
Childhood Absence Epilepsy Juvenile Absence Epilepsy
1 trial -
brivaracetam, brivaracetam, brivaracetam, brivaracetam
Lacuna Pharma Pty Ltd
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
1 trial -
sotatercept, PL1 - Powder for injection
Lacuna Pharma Pty Ltd
Therapeutic confirmatory (phase III)
1 trial -
sotatercept, sotatercept
Lacuna Pharma Pty Ltd
Pulmonary Arterial Hypertension (PAH)
1 trial
Frequently asked questions
How many pipeline programs does Anaxis Pharma have?
198 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs